锦欣生殖(01951.HK)拟收购武汉黄浦医院75%股权
格隆汇 6 月 29日丨锦欣生殖(01951.HK)宣布,于2020年6月29日,公司的间接全资附属公司四川锦欣与武汉黄浦中西医结合妇产医院有限责任公司("武汉黄浦医院")的若干股东("卖方")订立股权转让协议,据此,四川锦欣将收购武汉黄浦医院的合共75%股权(其中70%股权将由四川锦欣持有,5%股权未来将由四川锦欣指定的独立法定主体持有以用于员工激励目的)。于收购事项完成后,武汉黄浦医院将成为集团的非全资附属公司。
据悉,武汉黄浦医院为一家位于中国湖北省武汉市江岸区的营利性三级专业妇产医院,其为武汉拥有体外受精("IVF")牌照以向患者提供辅助生殖服务("ARS")(包括常规体外受精及胚胎移植("IVF-ET")以及卵胞浆内单精子注射("ICSI"))仅有的两所非公立及营利性医院之一。
公告称,收购事项符合集团确立的战略,即凭藉其于中国的领先地位,通过专注于收购已具备常规IVF-ET及ICSI牌照且位于具有巨大市场潜力的地理位置的目标ARS供应商来拓展平台。湖北省有约5,927万人,然而,湖北省的ARS市场相对分散,没有任何绝对主导的ARS供应商。凭藉在四川省及广东省的成功经验,集团旨在成为湖北省领先的ARS供应商。此外,收购事项使集团能够战略性地将其业务拓展到人口众多及人均收入高的新地区。集团计划利用其品牌,整合现有资源及吸引区域市场的顶尖人才及关键意见领袖,以建立强大的医疗团队及满足未满足的医疗需求。此外,收购事项将进一步提高集团于中国ARS网络的市场份额、生产力及产能。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.